Skip to main content

LCTX

Stock
Health Care
Biotechnology

Performance overview

LCTX Price
Price Chart

Forward-looking statistics

Beta
1.30
Risk
86.99%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Company info

SectorHealth Care
IndustryBiotechnology
Employees60
Market cap$183.2M

Fundamentals

Enterprise value$160.2M
Revenue$9.6M
Revenue per employee—
Profit margin-169.57%
Debt to equity2.89

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$0.07
Dividend per share—
Revenue per share$0.05
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$6M
Put-call ratio—

Macro factor sensitivity

Growth-1.7
Credit+6.3
Liquidity+3.2
Inflation-3.6
Commodities-2.5
Interest Rates-2.9

Valuation

Dividend yield0.00%
PEG Ratio-6.73
Price to sales24.13
P/E Ratio-6.73
Enterprise Value to Revenue16.76
Price to book2.92

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend dayJanuary 4, 2016

News

Two Biotech Stocks Poised For Big Moves On Monday

Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology | Lineage Cell Therapeutics)

Benzinga (June 23, 2025)
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Lineage Cell (LCTX) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.

Zacks Investment Research (May 13, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free